McMaster prof working on cure for Type 1 diabetes

ORIGINAL ARTICLE, Ritika Dubey, The Hamilton Spectator, July 26, 2022

Q and A: Dr. Harald Stover and Allarta co-founder Maria Antonakos talk about new cell-based therapy, which alleviates need for insulin injections and immune-suppressive drugs.

There’s no cure for Type 1 diabetes. But soon, courtesy of a Hamilton-based company, there could be one.

Dr. Harald Stover, a chemistry professor at McMaster University and co-founder of Allarta Life Sciences, is behind breakthrough research that aims to cure diabetes with a cell-based therapy, in which new curative cells transplanted into the body do the work to produce insulin — alleviating the need for injections and immune-suppressive drugs.

The technology, born in a McMaster laboratory, is in the early stages of implementation in Canada — 100 years after Canadian researchers developed therapeutic insulin, changing the lives of diabetics around the world.

To continue reading, CLICK HERE.


Learn more about Allarta Life Sciences.

Share this article
Facebook
Twitter
LinkedIn
WhatsApp
Email
View All Categories

Featured iF Clients

Celebrate BIG ideas that make a bigger impact at The Big DiF, Innovation Factory’s annual open house and client showcase. Join 250+ people from the Hamilton-Halton community to celebrate entrepreneurship and innovation.

Join Innovation Factory's Annual Open House - The Big DiF!

Network with 250+ industry professionals, discover emerging solutions from our innovators, and celebrate entrepreneurship within the Hamilton-Halton ecosystem.

May 9, 2024 | 4:00pm – 8:00pm | Hamilton, Ontario
A 6-week training & mentorship program that offers startups and growing businesses opportunities to build strategic connections, and prepare to secure investment capital.

Ready to accelerate your business growth?

Founders Fast Track is 6 week mentorship program that provides your startup with access to industry expertise, resources, networking opportunities, and skills to help you secure investment capital.

Applications are open until April 14, 2024